Lipid-Polyglutamate Nanoparticle Vaccine Platform.

Van Lysebetten, Dorien et al.·ACS applied materials & interfaces·2021·Moderate Evidenceanimal
RPEP-05838AnimalModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal
Evidence
Moderate Evidence
Sample
Mouse models (in vivo immunization studies)
Participants
Mouse models (in vivo immunization studies)

What This Study Found

PGA-based lipid nanoparticles co-delivering peptide antigen and TLR7/8 agonist activated antigen-specific T cells in mice via both subcutaneous and IV routes.

Key Numbers

PGA-Ag + PGA-IMDQ co-delivered; ionizable lipid LNP; SC and IV routes; innate immune cell uptake confirmed; Ag-specific T cells induced

How They Did This

Lab and animal study. Conjugated peptide antigen and IMDQ adjuvant to PGA. Condensed into lipid nanoparticles with ionizable lipid. Tested uptake by immune cells and T-cell activation in mouse models.

Why This Research Matters

A universal platform for co-delivering any peptide antigen with immune boosters could accelerate personalized cancer vaccine development.

What This Study Doesn't Tell Us

Animal study in mice. Efficacy against actual tumors not tested. Human immune responses may differ. Specific peptide antigens tested were limited.

Trust & Context

Original Title:
Lipid-Polyglutamate Nanoparticle Vaccine Platform.
Published In:
ACS applied materials & interfaces, 13(5), 6011-6022 (2021)
Database ID:
RPEP-05838

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-05838·https://rethinkpeptides.com/research/RPEP-05838

APA

Van Lysebetten, Dorien; Malfanti, Alessio; Deswarte, Kim; Koynov, Kaloian; Golba, Bianka; Ye, Tingting; Zhong, Zifu; Kasmi, Sabah; Lamoot, Alexander; Chen, Yong; Van Herck, Simon; Lambrecht, Bart N; Sanders, Niek N; Lienenklaus, Stefan; David, Sunil A; Vicent, María J; De Koker, Stefaan; De Geest, Bruno G. (2021). Lipid-Polyglutamate Nanoparticle Vaccine Platform.. ACS applied materials & interfaces, 13(5), 6011-6022. https://doi.org/10.1021/acsami.0c20607

MLA

Van Lysebetten, Dorien, et al. "Lipid-Polyglutamate Nanoparticle Vaccine Platform.." ACS applied materials & interfaces, 2021. https://doi.org/10.1021/acsami.0c20607

RethinkPeptides

RethinkPeptides Research Database. "Lipid-Polyglutamate Nanoparticle Vaccine Platform." RPEP-05838. Retrieved from https://rethinkpeptides.com/research/van-2021-lipidpolyglutamate-nanoparticle-vaccine-platform

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.